In mAbxience we strive to ensure that our biosimilars delivered to patients are highly similar to the reference products.
This is not our goal – it is the very essence of how we work. A methodology that guides us in each of our decisions. A focus on quality throughout the entire development process. We call it fingerprint-like, biosimilars by design.
Our work methodology is our identity, focused on quality and efficacy. It defines and differentiates us, resulting in the delivery of the highest quality products to patients all over the world.
That is the reason why we choose only the latest technology, to develop the very best products.